BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vellas C, Tremeaux P, Del Bello A, Latour J, Jeanne N, Ranger N, Danet C, Martin-Blondel G, Delobel P, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with Sotrovimab. Clin Microbiol Infect 2022:S1198-743X(22)00258-0. [PMID: 35595125 DOI: 10.1016/j.cmi.2022.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ordaya EE, Vergidis P, Razonable RR, Yao JD, Beam E. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. J Clin Virol 2023;160:105382. [PMID: 36731147 DOI: 10.1016/j.jcv.2023.105382] [Reference Citation Analysis]
2 Owen A, Diaz JV, Guyatt G, Lamontagne F, Stegemann M, Vandvik PO, Agoritsas T. WHO Living Guidelines on antivirals for COVID-19 are evidence-based. Lancet 2022;400:2196-8. [PMID: 36372074 DOI: 10.1016/S0140-6736(22)02306-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Akinosoglou K, Rigopoulos EA, Kaiafa G, Daios S, Karlafti E, Ztriva E, Polychronopoulos G, Gogos C, Savopoulos C. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Viruses 2022;15. [PMID: 36680160 DOI: 10.3390/v15010118] [Reference Citation Analysis]
4 Farhadian N, Farhadian M, Zamanian MH, Taghadosi M, Vaziri S. Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. Immunopharmacology and Immunotoxicology 2022. [DOI: 10.1080/08923973.2022.2160733] [Reference Citation Analysis]
5 Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis 2022:ciac868. [PMID: 36326680 DOI: 10.1093/cid/ciac868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Salvadori M. What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic. Transplantology 2022;3:288-306. [DOI: 10.3390/transplantology3040030] [Reference Citation Analysis]
7 Vellas C, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment. J Infect 2022;85:e162-3. [PMID: 35878684 DOI: 10.1016/j.jinf.2022.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
8 Del Bello A, Marion O, Izopet J, Kamar N. Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients? Viruses 2022;14:1860. [DOI: 10.3390/v14091860] [Reference Citation Analysis]
9 Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Cabié A, Choquet C, Coustillères F, Martellosio JP, Gaube G, Trinh-Duc A, Ronchetti AM, Pourcher V, Chauveau M, Lacombe K, Peiffer-Smadja N, Housset P, Perrot A, Pialoux G, Martin A, Dubee V, Devaux M, Frey J, Cazanave C, Liblau R, Carrat F, Yordanov Y. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. J Infect 2022:S0163-4453(22)00406-6. [PMID: 35803386 DOI: 10.1016/j.jinf.2022.06.033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Teo SP, Department of Internal Medicine, RIPAS Hospital, Bandar Seri Begawan, BA 1710, Brunei Darussalam.. Sotrovimab for treatment of COVID-19 infections. APT 2022;4:56-59. [DOI: 10.31491/apt.2022.06.087] [Reference Citation Analysis]